Tempus AI, Inc. (NASDAQ:TEM) COO Ryan Fukushima Sells 20,000 Shares

Tempus AI, Inc. (NASDAQ:TEM) COO Ryan Fukushima sold 20,000 shares of the company’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $62.50, for a total transaction of $1,250,000.00. Following the completion of the sale, the chief operating officer now directly owns 962,442 shares in the company, valued at approximately $60,152,625. The trade was a 2.04 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Ryan Fukushima also recently made the following trade(s):

• On Tuesday, January 7th, Ryan Fukushima sold 20,000 shares of Tempus AI stock. The shares were sold at an average price of $39.61, for a total transaction of $792,200.00.
• On Monday, December 16th, Ryan Fukushima sold 3,500 shares of Tempus AI stock. The shares were sold at an average price of $40.23, for a total transaction of $140,805.00.
• On Wednesday, December 11th, Ryan Fukushima sold 120,000 shares of Tempus AI stock. The shares were sold at an average price of $42.51, for a total transaction of $5,101,200.00.

Tempus AI Stock Down 6.1 %

Shares of NASDAQ:TEM opened at $64.99 on Friday. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. Tempus AI, Inc. has a 1 year low of $22.89 and a 1 year high of $79.49. The stock’s fifty day moving average price is $44.36 and its 200-day moving average price is $48.84.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Stifel Nicolaus cut shares of Tempus AI from a “buy” rating to a “hold” rating and increased their price target for the company from $45.00 to $65.00 in a report on Monday, November 11th. Needham & Company LLC restated a “buy” rating and set a $56.00 target price on shares of Tempus AI in a research report on Tuesday, January 14th. Guggenheim began coverage on shares of Tempus AI in a research report on Monday, December 9th. They set a “buy” rating and a $74.00 target price on the stock. Wolfe Research began coverage on shares of Tempus AI in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 target price on the stock. Finally, TD Cowen restated a “buy” rating and set a $74.00 target price (up previously from $58.00) on shares of Tempus AI in a research report on Wednesday. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $58.55.

Institutional Investors Weigh In On Tempus AI

A number of hedge funds have recently added to or reduced their stakes in TEM. First Horizon Advisors Inc. bought a new stake in shares of Tempus AI in the third quarter worth $30,000. FNY Investment Advisers LLC bought a new stake in shares of Tempus AI during the 4th quarter valued at about $67,000. IFP Advisors Inc purchased a new stake in shares of Tempus AI during the 4th quarter valued at about $76,000. US Bancorp DE bought a new position in shares of Tempus AI in the 4th quarter worth approximately $80,000. Finally, Vestor Capital LLC purchased a new position in shares of Tempus AI in the third quarter worth approximately $153,000. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.